Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 11, 2013

Pharmacyclics Achieves Another $50M Milestone

  • Pharmacyclics' wallet just got a little heavier: the Phase III clinical trial RESONATE™-2 just enrolled its fifth patient, subsequently triggering a fourth $50 million milestone payment obligation from Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

    This trial is a randomized, multicenter, open-label Phase III study of ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in patients 65 years or older with treatment-naïve chronic lymphocytic leukemia/small lymphocyctic lymphoma (CLL/SLL). The study is designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival (PFS); the comparator is single-agent chlorambucil. This global study is planned to enroll 272 patients worldwide.

    Pharmacyclics entered into a worldwide collaboration with Janssen in December of 2011 to develop and commercialize ibrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor. Pharmacyclics received from Janssen an up-front payment totaling $150 million upon signing the contract. To date, $200 million in milestones have been earned and Pharmacyclics may receive up to an additional $625 million in development and regulatory milestone payments for total potential up-front and milestone payments of $975 million.

    Milestone payments from Janssen to Pharmacyclics have all been triggered by the enrollment of a fifth patient in a clinical trial of ibrutinib. Pharmacyclics also received a $50 million payment from Janssen in early August after the Phase III clinical trial, RESONATE (PCYC-1112), of ibrutinib versus ofatumumab for patients with relapsed or refractory CLL/SLL, enrolled its fifth patient; after, later that month, the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) enrolled its fifth patient; and after the Phase III clinical trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL enrolled its fifth patient in October.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »